Previous work with the MC38 syngeneic mouse model shows that Hsp90 inhibitor treatment results in a decrease in tumour volume (Jaeger et al., 2019; Zavareh et al., 2021; Rahmy et al., 2022) as well as a decrease in surface levels of PD-L1 (Zavareh et al., 2021). This evidence concerns the gene CD274 and neoplasm.